BioSpace News Archive

Clover Biopharmaceuticals, Ltd. announced that it has established a commercial partnership with Keyuan Xinhai Medical Products Trading Co. Ltd., a leading pharmaceutical import and distribution company in China, as it prepares for the commercial launch of AdimFlu-S, the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China.

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that the U.S. Food and Drug Administration (FDA) approved XACDURO® (sulbactam for injection; durlobactam for injection).

Camurus announces that the US Food and Drug Administration has approved Brixadi™ extended release injection for subcutaneous use, a weekly and monthly medication for the treatment of moderate to severe opioid use disorder, in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a daily buprenorphine product.

Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for a Phase II study in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease.

Cypre positions to deliver in vitro animal-alternatives to the biopharma drug discovery industry with the recent passing of the FDA Modernization Act.

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today announced plans to present data at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.

TrialSpark, Inc. announced today that the first patient has been dosed in its Phase 2 clinical trial for ASN008-201, a topical sodium channel blocker in development for pruritus associated with atopic dermatitis (AD).

The Insight Partners published latest research report on “Radiopharmaceutical Theranostics Market Trends Report, Growth, Share, Size & Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Radioisotope, Source, Indication and End User”, the global market size is expected to grow from USD 1,814.58 million in 2022

iPredictTM AI Eye Screening System provides fully automated age-related macular degeneration (AMD) screening, including retinal imaging and immediate reporting of actionable results.

To better explain the prevalence and cause of clots, researchers from The Feinstein Institutes for Medical Research investigated the rates of clotting 90 days after patients leave the hospital.